Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 8/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 2/20 | 0.34 |
| ▸ | PLG | P00747 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948078 | 0.86 | BRS3 (0.42) | RORCCNR2F2LMNAMAPT | |
| SCHEMBL9987 | 0.81 | DGAT1 (0.44) | RORCCNR2F2PRSS1 | |
| SCHEMBL8434856 | 0.77 | RORC (0.53) | RORCCNR2F2F10PLG | |
| SCHEMBL20621008 | 0.75 | RORC (0.52) | RORCCNR2F2F10PLG | |
| SCHEMBL19115907 | 0.75 | LPL (0.36) | LMNAMAPTSMN1; SMN2TSHRTP53 | |
| SCHEMBL11426539 | 0.74 | RORC (0.51) | RORCCNR2MMP8OPRK1LMNA | |
| SCHEMBL1125293 | 0.74 | RORC (0.51) | RORCCNR2F2F10PLG | |
| SCHEMBL14393384 | 0.74 | RORC (0.51) | RORCCNR2MMP8OPRK1PPARA | |
| SCHEMBL15630699 | 0.74 | RORC (0.51) | RORCCNR2F2F10PLG | |
| SCHEMBL6279399 | 0.73 | CNR2 (0.58) | RORCCNR2F2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-11-02 | — | — | US | disclosed |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-3842420-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2022-08-02 | — | — | US | disclosed |
| EP-3842420-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-2912019-B1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS LLC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2020-11-12 | — | — | US | disclosed |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190055269-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2019-02-21 | — | — | US | disclosed |
| US-10093686-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2017-11-30 | — | — | US | disclosed |
| US-9777024-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2016-05-19 | — | — | US | disclosed |
| US-9221843-B2 | Heteroaryl inhibitors of PDE4 | Tetra Discovery Partners, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2912019-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | Tetra Discovery Partners, LLC | 2015-04-30 | — | — | US | disclosed |
| WO-2014066659-A9 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS, LLC. (US) | 2015-02-12 | — | — | WO | disclosed |
| WO-2014066659-A1 | HETEROARYL INHIBITORS OF PDE4 | TETRA DISCOVERY PARTNERS, LLC. (US) | 2014-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354384-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-20230024240-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-20150119362-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 1989/4885CNR2 2419/4885UCHL1 1397/4885 |
| US-11401286-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-20190055269-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-20230348501-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-20170342094-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-11767334-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-12264169-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-10093686-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-10626129-B2 | Heteroaryl inhibitors of PDE4 | PDE4A, PDE4B, PDE4C | RORC 426/4885CNR2 1911/4885UCHL1 1534/4885 |
| US-20160137672-A1 | HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | RORC 1989/4885CNR2 2419/4885UCHL1 1397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.